Blog

New hope for metastatic melanoma patients – Weill Cornell Medicine Meyer Cancer

Photo taken from Weill Cornell Medicine/X

Sep 22, 2024, 03:28

New hope for metastatic melanoma patients – Weill Cornell Medicine Meyer Cancer

Weill Cornell Medicine Meyer Cancer Center shared a post by Weill Cornell Medicine on X, adding the following:

“Check out the latest research from WCM Meyer Cancer Director Dr. Jedd Wolchok and colleagues, providing hope for patients with metastatic melanoma.”

Quoting Weill Cornell Medicine’s post:

“About half of patients with metastatic melanoma treated with a combo of immune checkpoint inhibitors survive cancer-free for 10 years or more, according to new trial findings led by WCM Meyer Cancer, Dana Farber, and Royal Marsden NHS.

Full story.”

Source: Weill Cornell Medicine Meyer Cancer Center/X and Weill Cornell Medicine/X

cancer cancer-free survival Dana-Farber Immune Checkpoint Inhibitors Jedd Wolchok metastatic melanoma Meyer Cancer Center OncoDaily Oncology Royal Marsden NHS Weill Cornell Medicine

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage